|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Triglycerides measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program.
|
30275531 |
2018 |
|
Child Development Disorders, Pervasive
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.
|
28540026 |
2017 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.
|
28540026 |
2017 |
|
Malignant Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Downregulation of ASPP1/ASPP2 and upregulation of iASPP were revealed to be associated with a poor prognosis and metastasis in several types of cancer.
|
29731851 |
2018 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Using genetic models, we linked the PDE4-regulated modulation of P85 activation to the oncogenic kinase SYK.<b>Conclusions:</b> These data demonstrate that roflumilast and idelalisib suppress PI3K by distinct mechanisms, explaining the basis for their synergism, and suggest that the repurposing of PDE4 inhibitors to treat BCR-dependent malignancies is warranted.<i></i>.
|
29246942 |
2018 |
|
Malignant Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
All class IA p110 subunits interact with p85 regulatory subunits, and mutations/deletions in different p85 regulatory subunits have been identified in both cancer and primary immunodeficiencies.
|
29616047 |
2018 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
In addition, the combination of P85 and (-)-gossypol effectively reduced clonogenic survival of A549 cells: (11 ± 5%) compared to (-)-gossypol and P85 alone (62 ± 27% and 93 ± 13%, respectively), and enhanced radiation cancer cell killing.
|
27827005 |
2017 |
|
Malignant Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Mutation or loss of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) is emerging as a transforming factor in cancer, but the mechanism of transformation has been controversial.
|
28630349 |
2017 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
EGR-1/ASPP1, therefore, may be potentially used as therapeutic targets to improve cancer's response to pro-apoptosis treatments.
|
28594407 |
2017 |
|
Malignant Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In conclusion, our study provides a proof of concept that blocking the interaction of p110α with p85 by a peptide can serve as a new strategy to inhibit the oncogenic activity of PI3K in cancer therapy.
|
28743532 |
2017 |
|
Malignant Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity.
|
23270540 |
2012 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
|
16131837 |
2005 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The p85 isoform of the kinase S6K1 functions as a secreted oncoprotein to facilitate cell migration and tumor growth.
|
29588411 |
2018 |
|
Primary malignant neoplasm
|
0.080 |
GeneticVariation
|
group |
BEFREE |
All class IA p110 subunits interact with p85 regulatory subunits, and mutations/deletions in different p85 regulatory subunits have been identified in both cancer and primary immunodeficiencies.
|
29616047 |
2018 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Downregulation of ASPP1/ASPP2 and upregulation of iASPP were revealed to be associated with a poor prognosis and metastasis in several types of cancer.
|
29731851 |
2018 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In vivo, P85 (200 mg/kg/day) and (-)-gossypol (15 mg/kg/day) could be safely injected intravenously over 5 days and enhanced radiation-related tumor control in an A549 xenograft model.
|
27827005 |
2017 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In addition, lower ASPP1 was closely related to the higher grade of tumors and shorter life expectancy of ccRCC patients, both with p < 0.001.
|
28656647 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
EGR-1/ASPP1, therefore, may be potentially used as therapeutic targets to improve cancer's response to pro-apoptosis treatments.
|
28594407 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Mutation or loss of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) is emerging as a transforming factor in cancer, but the mechanism of transformation has been controversial.
|
28630349 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
In addition, the combination of P85 and (-)-gossypol effectively reduced clonogenic survival of A549 cells: (11 ± 5%) compared to (-)-gossypol and P85 alone (62 ± 27% and 93 ± 13%, respectively), and enhanced radiation cancer cell killing.
|
27827005 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
In conclusion, our study provides a proof of concept that blocking the interaction of p110α with p85 by a peptide can serve as a new strategy to inhibit the oncogenic activity of PI3K in cancer therapy.
|
28743532 |
2017 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The short isoform p42 Ebp1, which is actual binding partner of ErbB3 has been implicated as a tumor suppressor with many binding partners such as Rb, HDAC2, Sin3A and the p85 subunit of PI3K with HSP70/CHIP, inhibiting its own antiproliferative activity or inhibiting PI3K activity.
|
27130196 |
2016 |
|
Primary malignant neoplasm
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity.
|
23270540 |
2012 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Analyses of 51 paired HCC and surrounding nontumor tissues revealed that methylation of ASPP1 and ASPP2 was associated with the decreased expression of ASPP1 and ASPP2 in tumor tissues and the early development of HCC.
|
20034025 |
2010 |